Logo
x

Search

Subscribe Now

Chugai

Chugai Received the MHLW’s Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for the Detection of Solid Tumor

Chugai Received the MHLW’s Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic for the Detection of So...

  • March 1, 2024
Chugai Reports the NDA Submission of Crovalimab to the MHLW for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Japan

Chugai Reports the NDA Submission of Crovalimab to the MHLW for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Japan

  • June 14, 2023
Chugai Receives the MHLW Approval for the Additional Indication of Polivy (polatuzumab vedotin) to Treat Diffuse Large B-cell Lymphoma

Chugai Receives the MHLW Approval for the Additional Indication of Polivy (polatuzumab vedotin) to Treat Diffuse Large B-cell Lymp...

  • August 24, 2022
Chugai Entered into a License Agreement with Noile-Immune Biotech for PRIME CAR-T Technology

Chugai Entered into a License Agreement with Noile-Immune Biotech for PRIME CAR-T Technology

  • August 23, 2022
Chugai and Towa’s Edirol Receive the MHLW Approval for the Treatment of Osteoporosis

Chugai and Towa’s Edirol Receive the MHLW Approval for the Treatment of Osteoporosis

  • August 17, 2022
Chugai’s Herceptin Receives the MHLW’s Approval for the Treatment of Advanced or Recurrent HER2-Positive Salivary Gland Cancer

Chugai’s Herceptin Receives the MHLW’s Approval for the Treatment of Advanced or Recurrent HER2-Positive Salivary Gland Cancer

  • November 26, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.